Investors Get Bullish on ADCs; Mersana Closes $27M Round
Mersana Therapeutics Inc. attracted $27 million in Series A-1 financing for its Fleximer-based antibody-drug conjugate (ADC) pipeline. Riding the coattails of Adcetris' success, Mersana is hoping to develop the next generation of ADCs, addressing limitations of earlier iterations of the technology.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST